Lifitegrast Brand Name– XIIDRA
What is Lifitegrast
Lifitegrast ophthalmic solution is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated to treat signs and symptoms associated with dry eye disease (DED).
During 4 clinical trials comparing lifitegrast to a placebo vehicle, drug recipients noted an improvement in the eye dryness score (EDS) by treatment day 42. In 2 of the 4 studies, the EDS was significantly improved by treatment day 14.
The most common adverse events associated with drug administration include instillation site irritation, dysgeusia, and reduced visual acuity.
Lifitegrast was approved by the FDA for use in patients 17 years and older in July 2016
Indications
- xerophthalmia
For the treatment of xerophthalmia associated with dry eye disease (keratoconjunctivitis sicca)
Side Effects
- anaphylactoid reactions
- angioedema
- blurred vision
- bronchospasm
- conjunctival hyperemia
- conjunctivitis
- dysgeusia
- dyspnea
- headache
- lacrimation
- ocular discharge
- ocular inflammation
- ocular irritation
- ocular pruritus
- rash
- sinusitis
- urticaria
- visual impairment
Monitoring Parameters
- ophthalmologic exam
Contraindications
- breast-feeding
- contact lenses
- pregnancy
Lifitegrast should not be administered while wearing contact lenses. Contact lenses should be removed prior to administration of the drug. Lenses may be reinserted 15 minutes following administration of the drug
Interactions
There are no drug interactions associated with Lifitegrast products.
